SLC5A2 and acute kidney injury: Contemporary labeling specifies that eGFR should be ≥30mL/min/1.73 m2 for canagliflozin initiation, ≥25 mL/min/1.73m2 for dapagliflozin, and >20 mL/min/1.73 m2for empagliflozin if being used for the treatment of HF.86, -88Importantly, initiation of an SGLT2 inhibitor induces a reversible drop ineGFR of 3 to 4 mL/min/1.73 m2 in 60% to 70% of individuals—aneffect that is not associated with progressive long-term kidney functionloss or AKI.